AU2008231306A1 - Acute transmitted HIV envelope signatures - Google Patents

Acute transmitted HIV envelope signatures Download PDF

Info

Publication number
AU2008231306A1
AU2008231306A1 AU2008231306A AU2008231306A AU2008231306A1 AU 2008231306 A1 AU2008231306 A1 AU 2008231306A1 AU 2008231306 A AU2008231306 A AU 2008231306A AU 2008231306 A AU2008231306 A AU 2008231306A AU 2008231306 A1 AU2008231306 A1 AU 2008231306A1
Authority
AU
Australia
Prior art keywords
hiv
transmitted
env
consensus
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008231306A
Other languages
English (en)
Inventor
Tanmoy Bhattacharya
Feng Gao
Gnana S. Gnanakaran
Beatrice H. Hahn
Barton F. Haynes
Bette T. Korber
George Shaw
Ron Swanstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
UAB Research Foundation
University of California San Diego UCSD
Duke University
Original Assignee
University of North Carolina at Chapel Hill
UAB Research Foundation
University of California Berkeley
University of California San Diego UCSD
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, UAB Research Foundation, University of California Berkeley, University of California San Diego UCSD, Duke University filed Critical University of North Carolina at Chapel Hill
Publication of AU2008231306A1 publication Critical patent/AU2008231306A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2008231306A 2007-03-27 2008-03-27 Acute transmitted HIV envelope signatures Abandoned AU2008231306A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90725907P 2007-03-27 2007-03-27
US60/907,259 2007-03-27
PCT/US2008/003965 WO2008118470A2 (en) 2007-03-27 2008-03-27 Acute transmitted hiv envelope signatures

Publications (1)

Publication Number Publication Date
AU2008231306A1 true AU2008231306A1 (en) 2008-10-02

Family

ID=39789201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008231306A Abandoned AU2008231306A1 (en) 2007-03-27 2008-03-27 Acute transmitted HIV envelope signatures

Country Status (7)

Country Link
US (1) US20100104596A1 (enExample)
EP (1) EP2129395A4 (enExample)
JP (1) JP2010530356A (enExample)
CN (1) CN101969997A (enExample)
AU (1) AU2008231306A1 (enExample)
CA (1) CA2682206A1 (enExample)
WO (1) WO2008118470A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
WO2011109104A2 (en) * 2010-03-03 2011-09-09 The Uab Research Foundation Molecular clone of hiv-1
WO2011126576A2 (en) * 2010-04-09 2011-10-13 Duke University Genetic signatures in the envelope glycoprotein of hiv-1
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
US20030215793A1 (en) * 2002-01-17 2003-11-20 Hahn Beatrice H. Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
CN1852734B (zh) * 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
DE10343901A1 (de) * 2003-09-19 2005-04-14 Basf Ag Amidgruppenhaltige Ethylenterpolymere und ihre Verwendung
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies

Also Published As

Publication number Publication date
EP2129395A2 (en) 2009-12-09
WO2008118470A2 (en) 2008-10-02
WO2008118470A3 (en) 2010-03-11
JP2010530356A (ja) 2010-09-09
US20100104596A1 (en) 2010-04-29
CN101969997A (zh) 2011-02-09
EP2129395A4 (en) 2012-05-09
CA2682206A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
Casimiro et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
US10149902B2 (en) Swarm immunization with envelopes from CH505
Paris et al. Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
Burgers et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial
Bailey An assessment of the role of chimpanzees in AIDS vaccine research
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
Johnston et al. Progress in HIV vaccine development
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
AU2015240883B2 (en) Compositions comprising CH848 envelopes and uses thereof
Willey et al. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles
Matchett et al. Divergent HIV-1-directed immune responses generated by systemic and mucosal immunization with replicating single-cycle adenoviruses in rhesus macaques
Stratov et al. Vaccines and vaccine strategies against HIV
US20100104596A1 (en) Acutte transmitted hiv envelope signatures
CA2538840C (en) Dna vaccine compositions and methods of use
Barnett et al. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C
Beena et al. Human immunodeficiency virus vaccine an update
HK1153677A (en) Acute transmitted hiv envelope signatures
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
McGettigan et al. HIV-1 vaccines: the search continues
Sui et al. Vaccine strategies to prevent mucosal transmission of HIV-1
US20050112138A1 (en) Aids vaccines
Aidoo et al. 7 Modification of HIV-Envelope Glycoprotein to Enhance Immunogenicity
WO2016172070A1 (en) Swarm immunization with envelopes from ch505
Elizaga et al. Progress in the development of a preventive HIV-1 vaccine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO-APPLICANT NAME FROM THE UNIVERSITY OF ALABAMA AT BIRMINGHAM TO THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted